Canopy Growth Withdraws Medical Marijuana Strain Penelope In Poland, Citing Aging Genetics, Quality Concerns

Canopy Growth’s (NASDAQ:CGC) international subsidiary Canopy Growth Polska is withdrawing its medical marijuana strain Penelope from the market, writes Born2Invest. One of the leading suppliers of medical marijuana in Poland decided to withdraw the popular strain that contains 8% THC and 7% CBD due to the aging of the strain, which has made its quality unstable.

“The decision to discontinue Penelope was very difficult for us, as it is a strain that enjoyed huge interest. However, our commitment to providing only the highest quality products forced us to take this step,” said a representative of Canopy Growth Polska.

The Penelope strain was one of the company’s flagship products, mostly because of its balanced content of the cannabinoids. However, over time, the genetics of the plant can weaken, …

Full story available on Benzinga.com